The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children.

开始日期2028-01-01

申办/合作机构

Stanford University

NCT06439862 / Not yet recruitingN/AIIT

Quality of Life in School Aged-children With Posterior Urethral Valves

Posterior urethral valves (PUV) are the most common congenital obstructive lesion of the urethra, affecting from 1 per 3000 to 1 per 8000 live births. Valve ablation usually resolves the obstruction in PUV but patients still may suffer of deterioration in renal and urinary functions.
Renal insufficiency is the most feared long-term complication. Up to 50 % of the patients will develop chronic kidney disease (CKD), and up to 20 % will develop end-stage renal disease (ESRD) and ultimately will require kidney transplantation. PUV is the first urological cause of ESRD. Progression towards CKD depends on febrile urinary tract infections (UTIs), severity of a vesicoureteral reflux and bladder dysfunction.
Bladder dysfunction is due to an overactive and small poorly compliant bladder during infancy. Detrusor overactivity usually decreases in childhood and bladder capacity increases. The most common symptom of this bladder dysfunction is urinary incontinence. 60 % of children are continent at the age of 5 years old and 90 % at 10 years old. In case of persistent bladder dysfunction, medical treatment (anticholinergics, alpha-blockers) may be introduced, or even intermittent catheterizations.
Current scientific literature has very few studies on quality of life (QoL) in patients with PUV, mostly in adult patients and very small cohorts. Men treated for PUV in childhood had a good quality of life compared to the normative population, except for sleeping, eating and sexual activity. It seemed that the more severe the urological and nephrological functions were, the lower the QoL was. Children were only asked about intermittent urinary catheterization, and family point of view has never been collected. However, QoL and long-term evolution represent the first concerns of parents-to-be in prenatal counseling, or after diagnosis in an infant with PUV.
Hence, the aim of the study is to investigate the quality of life in school-aged children who had been treated for PUV in their first year of life, as measured by the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0).

开始日期2025-07-01

申办/合作机构

Hospices Civils de Lyon

NCT05421156 / Not yet recruitingN/AIIT

Evaluation of Long-term Sexual Dysfunctions, Urinary Dysfunctions and Pelvic Organ Prolapse in Women Who Underwent Laparoscopic Subtotal Versus Total Hysterectomy for Benign Conditions

Hysterectomy is one of the most commonly performed gynecologic surgeries in the USA. It is used for many benign conditions such as leiomyoma and abnormal uterine bleeding. Surgery may involve the removal of the cervix (total hysterectomy, TH) or its preservation (supracervical or subtotal hysterectomy, SH). Whether TH or SH is the best procedure for benign conditions is a matter of debate. Considering the lack of evidence, this study aims to evaluate long-term sexual dysfunctions, urinary dysfunctions and pelvic organ prolapse in women who underwent laparoscopic subtotal versus total hysterectomy for benign conditions.

开始日期2024-07-01

申办/合作机构

University of Palermo

100 项与膀胱功能障碍相关的临床结果

登录后查看更多信息

100 项与膀胱功能障碍相关的转化医学

登录后查看更多信息

0 项与膀胱功能障碍相关的专利（医药）

登录后查看更多信息

5,409

项与膀胱功能障碍相关的文献（医药）

2025-01-01·Experimental Neurology

Time-dependent arachidonic acid metabolism and functional changes in rats bladder tissue after suprasacral spinal cord injury

Article

作者: Shuang, Weibing ; Sun, Ke ; Kang, Yinbo ; Wen, Jie ; Gong, Qian ; Zhang, Wenlong ; Rong, Yi

BACKGROUNDA critical aspect affecting the quality of life in Traumatic spinal cord injury (TSCI) patients is bladder dysfunction. Metabolities in arachidonic acid are crucial lipid signaling molecules involved innumerous physiological processes. In this study, We are the first use eicosanoid metabolomics detrusor contraction examine, to assess the effect of the arachidonic acid metabolic in bladder dysfunction following TSCI. In additon, we explore the time of inflammatory and function changes in bladder tissue.METHODSAdult male Sprague-Dawley rats were subjected to improved Weight Drop method surgeries. Detrusor contraction examination, urodynamic examination, eicosanoid metabolomics, transmission electron microscopy, Elisa and histological staining were performed to assess the change of inflammatory, metabolic and function variation over time after TSCI.RESULTSFollowing TSCI, before the variations of bladder function, inflammatory changes including the increase of inflammatory factors, mitochondrial damage, and slight lipid peroxidation, occurred in bladder tissue. And the inflammatory changes gradually decreases over time. However, From the third day after TSCI, secondary lesions appeared in bladder tissue. Not only did inflammation-related indexes increase again, the degree of mitochondrial damage and lipid peroxidation increased, but also the contractility of detrusor began to change significantly. We also found that the content of metabolites in arachidonic acid metabolic pathway and the degree of detrusor contractility change showed a strong correlation. In addition, we found that rats had moved beyond the spinal shock stage on the seventh day after TSCI.CONCLUSIONAltogether, we are the first to demonstrate that abnormal arachidonic acid metabolism plays an important role in bladder dysfunction after TSCI. We also demonstrate that 3d is a critical juncture for changes in rat bladder tissue, which indicates it is an important juncture in the treatment of neurogenic bladder.

2024-12-31·Gut Microbes

Lack of gut microbiome recovery with spinal cord injury rehabilitation

Article

作者: Amir, Amnon ; Braun, Tzipi ; Glick Saar, Efrat ; Zeilig, Gabriel ; Toren, Itamar ; Efroni, Gilat ; Haberman, Yael ; Gur Arie, Ayelet ; Hadar, Rotem ; Madar, Zecharia

Spinal cord injury (SCI) is a devastating event that significantly changes daily function and quality of life and is linked to bowel and bladder dysfunction and frequent antibiotic treatment. We aimed to study the composition of the gut microbiome in individuals with SCI during the initial sub-acute rehabilitation process and during the chronic phase of the injury. This study included 100 fecal samples from 63 participants (Median age 40 years, 94% males): 13 cases with SCI in the sub-acute phase with 50 longitudinal samples, 18 cases with chronic SCI, and 32 age and gender-matched controls. We show, using complementary methods, that the time from the injury was a dominant factor linked with gut microbiome composition. Surprisingly, we demonstrated a lack of gut microbial recovery during rehabilitation during the sub-acute phase, with further deviation from the non-SCI control group in the chronic ambulatory SCI group. To generalize the results, we were able to show significant similarity of the signal when comparing to a previous cohort with SCI, to subjects from the American Gut Project who reported low physical activity, and to subjects from another population-based cohort who reported less normal stool consistency. Restoration of the microbiome composition may be another desirable measure for SCI recovery in the future, but further research is needed to test whether such restoration is associated with improved neurological outcomes and quality of life.

2024-12-31·NMC Case Report Journal

Thoracic Intra and Extramedullary Capillary Hemangioma with Subacute Clinical Course: A Case Report and Literature Review

作者: Honda, Fumiaki ; Shirakura, Takahiro ; Yamamoto, Yumeki ; Shimauchi-Ohtaki, Hiroya ; Yokoo, Hideaki ; Miyagishima, Takaaki ; Shintoku, Ryosuke ; Aihara, Masanori ; Aramaki, Keigo ; Yoshimoto, Yuhei

Capillary hemangiomas are benign tumors comprising a lobulated proliferation of capillary vessels frequently located in the soft tissues of the neck and head. Spinal intradural capillary hemangiomas are rare, particularly intramedullary lesions. To our knowledge, only 31 cases of spinal intramedullary capillary hemangiomas have been reported. Here, we describe a rare case of a thoracic capillary hemangioma comprising extramedullary and intramedullary components. A 51-year-old male patient presented with bilateral lower extremity numbness and subsequent paraparesis, sensory disturbance, and bladder-bowel dysfunction with a subacute clinical course. Magnetic resonance imaging revealed a mass lesion with intramedullary and intradural extramedullary components at the Th9-10 vertebrae level and widespread spinal cord edema. Contrast-enhanced computed tomography revealed abnormal vessels on the dorsal spinal cord surface. Spinal angiography revealed a light-stained mass lesion fed by the radiculopial artery from the right Th11 intercostal artery. The tumor was resected en bloc, and the histological diagnosis was a capillary hemangioma. Postoperatively, the spinal cord edema diminished, and the patient was discharged from the convalescent rehabilitation ward. Although intramedullary capillary hemangioma is a rare spinal tumor and its preoperative diagnosis is difficult, it should be considered in the differential diagnosis of spinal intramedullary tumors.

102

项与膀胱功能障碍相关的新闻（医药）

2024-10-22

·PRNewswire

Dignify Therapeutics Selected as a Praxis SCI Accelerate Company

RESEARCH TRIANGLE PARK, N.C, Oct. 22, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program. SCI Accelerate is a commercialization program 'geared towards healthcare companies with a product ready to launch into market that will transform the lives of people living with SCI'. Under the SCI Accelerate program, Dignify and Praxis will focus on development of Dignify's drug programs to treat bladder and bowel disorders in people with SCI. Dr. Karl B. Thor, Chief Scientific Officer of Dignify, indicated; "The Praxis SCI Accelerate Program is critically important for Dignify to ensure that the clinical development program for our products provides the efficacy, safety, and convenience that are considered valuable and most important by SCI individuals for control of bowel and bladder dysfunction. The selection of Dignify to join the Praxis SCI community confirms the unmet medical need for our therapeutics." Arushi Raina, Praxis Director of Commercialization, stated "The Praxis team was impressed by the Dignify team's approach and excited by the possibility of a bowel and bladder treatment that could be used in an accessible way to transform daily living." About Dignify Therapeutics Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify's mission is to provide safe, effective, practical and convenient, "on-demand" pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About Praxis Praxis is a Canadian-based not-for-profit organization that leads global collaboration in SCI research, innovation and care. We accelerate the translation of discoveries and best practices into improved treatments for people with spinal cord injuries. Our work is driven by the priorities of people with SCI and led by our four teams — PLEX (people with lived experience), Cure, Care and Commercialization. PRESS CONTACT Dignify Therapeutics Anthony DiTonno, CEO 2 Davis Drive Research Triangle Park, NC 27709 [email protected] dignifytherapeutics.com SOURCE Dignify Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-15

·PRNewswire

Dignify to highlight recent accomplishments at the 2024 BIO Investor Forum

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, announced that Tony DiTonno, CEO and Executive Chairman, will provide a status update on the company's two lead drug development programs on Wednesday, Oct 16, as part of the BIO Investor Forum in San Francisco. "I look forward to sharing the company's incredible progress and dynamic drug development strategies with potential investors and partners in San Francisco. Dignify continues to advance its two lead drug programs to the clinic, fueled by over $20 million in non-dilutive funding. In the muti-billion-dollar market of bladder and bowel disorders, these programs represent novel therapies for severely underserved patient populations. Our novel development approach is rapid, de-risked and capital efficient," stated Mr. DiTonno. As a serial entrepreneur, Mr. DiTonno has more than 25 years of senior leadership experience spanning the pharmaceutical, biotechnology, and medical device industries. He has a long record of success in launching startups in the pharmaceutical and medical technology industries, extensive experience in raising capital and securing commercial and corporate partnerships, and strong product launch background in some of the most competitive and strictly regulated markets. The BIO Investor Forum is an annual conference focused on accelerating the progress of new therapeutics technologies into commercialization. As one of the premier forums for facilitating interactions between entrepreneurs and investors, it also features presentations from industry experts and panel discussion focused on emerging trends in the life sciences. About Dignify Therapeutics Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify's mission is to provide safe, effective, practical and convenient, "on-demand" pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina. SOURCE Dignify Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-01

·PRNewswire

Dignify Therapeutics to Participate in the BIO Investor Forum, October 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 1, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a specialty pharma company focused on resorting bowel and bladder function in patients with neurological diseases will be a presenting company at the BIO Investor Forum in San Francisco at the Fairmount Hotel at 11:15am on October 16, 2024. Dignify is developing two products to treat bladder and bowel dysfunction associated with spinal cord injury, neurological diseases, diabetes and the elderly. Currently, many of these individuals require bladder catheterization for urination, and an invasive, time-consuming manual bowel program for defecation that is often performed by a caregiver. Dignify's lead drug program, DTI-301, is a suppository that patients use as-needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure. Our second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. DTI-117 is a small peptide that directly stimulates smooth muscle contraction in the bladder and bowel and produces voiding in less than 10 minutes. Additionally, the drug has a very short plasma half-life, is eliminated rapidly, and development is NIH-funded into clinical studies. Anthony DiTonno, Dignify CEO, stated "The BIO Investor Forum provides a platform for discussions with institutional investors and strategic partners. As our two drug products are approaching clinical trials, we look forward to presenting Dignify's novel approach to treating severe unmet medical needs for desperate patients in a multi-billion dollar market". About Dignify Therapeutics Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify's mission is to provide safe, effective, practical and convenient, "on-demand" pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SOURCE Dignify Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED